IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stake Decreased by Bourne Lent Asset Management Inc.

Bourne Lent Asset Management Inc. lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,854 shares of the company’s stock after selling 45 shares during the quarter. IDEXX Laboratories accounts for 8.5% of Bourne Lent Asset Management Inc.’s portfolio, making the stock its 4th largest position. Bourne Lent Asset Management Inc.’s holdings in IDEXX Laboratories were worth $20,978,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Riverview Trust Co purchased a new position in IDEXX Laboratories during the 1st quarter valued at $26,000. CHICAGO TRUST Co NA grew its holdings in shares of IDEXX Laboratories by 3.9% in the first quarter. CHICAGO TRUST Co NA now owns 3,195 shares of the company’s stock worth $1,725,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. grew its holdings in shares of IDEXX Laboratories by 12.9% in the first quarter. Steph & Co. now owns 333 shares of the company’s stock worth $180,000 after purchasing an additional 38 shares during the last quarter. Ballentine Partners LLC lifted its holdings in IDEXX Laboratories by 1.9% during the 1st quarter. Ballentine Partners LLC now owns 1,188 shares of the company’s stock valued at $641,000 after buying an additional 22 shares in the last quarter. Finally, RDA Financial Network bought a new stake in IDEXX Laboratories during the 1st quarter valued at about $605,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.8 %

IDEXX Laboratories stock traded down $3.92 during trading hours on Tuesday, reaching $487.57. The stock had a trading volume of 255,163 shares, compared to its average volume of 469,859. The company has a market cap of $40.27 billion, a price-to-earnings ratio of 47.58, a PEG ratio of 4.04 and a beta of 1.33. The business’s 50 day moving average price is $500.81 and its 200-day moving average price is $528.07. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. The firm had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Insider Activity

In related news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.18% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of research reports. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Barclays lowered their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.